Chromatin modifier enzymes, the histone code and cancer

被引:219
作者
Santos-Rosa, H
Caldas, C [1 ]
机构
[1] Univ Cambridge, Hutchison MRC Res Ctr, Dept Oncol, Canc Genom Program, Cambridge, England
[2] Univ Cambridge, Wellcome Trust Canc Res UK Gordon Inst Canc & Dev, Cambridge, England
关键词
histone code; cancer; histone acetylases; histone deacetylases; histone methylases; chromatin;
D O I
10.1016/j.ejca.2005.08.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In all organisms, cell proliferation is orchestrated by coordinated patterns of gene expression. Transcription results from the activity of the RNA polymerase machinery and depends on the ability of transcription activators and repressors to access chromatin at specific promoters. During the last decades, increasing evidence supports aberrant transcription regulation as contributing to the development of human cancers. In fact, transcription regulatory proteins are often identified in oncogenic chromosomal rearrangements and are overexpressed in a variety of malignancies. Most transcription regulators are large proteins, containing multiple structural and functional domains some with enzymatic activity. These activities modify the structure of the chromatin, occluding certain DNA regions and exposing others for interaction with the transcription machinery. Thus, chromatin modifiers represent an additional level of transcription regulation. In this review we focus on several families of transcription activators and repressors that catalyse histone post-translational modifications (acetylation, methylation, phosphorylation, ubiquitination and SUMOylation); and how these enzymatic activities might alter the correct cell proliferation program, leading to cancer. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2381 / 2402
页数:22
相关论文
共 272 条
[1]   Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice:: A model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration [J].
Alarcón, JM ;
Malleret, G ;
Touzani, K ;
Vronskaya, S ;
Ishii, S ;
Kandel, ER ;
Barco, A .
NEURON, 2004, 42 (06) :947-959
[2]   Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53 [J].
An, W ;
Kim, J ;
Roeder, RG .
CELL, 2004, 117 (06) :735-748
[3]   Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents [J].
Andersen, MK ;
Christiansen, DH ;
Kirchhoff, M ;
Pedersen-Bjergaard, J .
GENES CHROMOSOMES & CANCER, 2001, 31 (01) :33-41
[4]   Association of t(9;11)-MLL AF9 and trisomy 8 in an AML-M5 preceded by pancytopenia [J].
Anguita, E ;
Barrio, CG ;
González, FA ;
Ferro, MT ;
del Potro, E ;
Ropero, P ;
Villegas, A .
CANCER GENETICS AND CYTOGENETICS, 2000, 120 (02) :144-147
[5]  
Ariyama Y, 1998, GENE CHROMOSOME CANC, V23, P267, DOI 10.1002/(SICI)1098-2264(199811)23:3<267::AID-GCC10>3.3.CO
[6]  
2-0
[7]  
Avet-Loiseau H, 1999, GENE CHROMOSOME CANC, V26, P166, DOI 10.1002/(SICI)1098-2264(199910)26:2<166::AID-GCC9>3.0.CO
[8]  
2-P
[9]   Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins [J].
Ayton, PM ;
Cleary, ML .
ONCOGENE, 2001, 20 (40) :5695-5707
[10]   Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain [J].
Bannister, AJ ;
Zegerman, P ;
Partridge, JF ;
Miska, EA ;
Thomas, JO ;
Allshire, RC ;
Kouzarides, T .
NATURE, 2001, 410 (6824) :120-124